SIRT2 and cancer: With preclinical proof of pharmacological potential of selective SIRT2 inhibitors to treat various modalities of cancer, or to synergize with existing therapies, including immunotherapies, selective SIRT2 inhibitors could prove to be a valuable asset to the existing palette of drugs in the emerging era of personalized medicine.